MA32509B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA32509B1
MA32509B1 MA33564A MA33564A MA32509B1 MA 32509 B1 MA32509 B1 MA 32509B1 MA 33564 A MA33564 A MA 33564A MA 33564 A MA33564 A MA 33564A MA 32509 B1 MA32509 B1 MA 32509B1
Authority
MA
Morocco
Prior art keywords
organic compounds
formula
methods
relates
pharmaceutical preparations
Prior art date
Application number
MA33564A
Other languages
Arabic (ar)
English (en)
Inventor
Christopher Adams
Qi-Ying Hu
Leslie Wighton Mcquire
Julien Papillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32509B1 publication Critical patent/MA32509B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur de nouveaux composés organique de formule (i), sur leurs méthodes d'utilisation, et sur des préparations pharmaceutiques les contenant.
MA33564A 2008-06-27 2011-01-26 Composes organiques MA32509B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7645208P 2008-06-27 2008-06-27
PCT/EP2009/057947 WO2009156462A2 (fr) 2008-06-27 2009-06-25 Composés organiques

Publications (1)

Publication Number Publication Date
MA32509B1 true MA32509B1 (fr) 2011-07-03

Family

ID=41445020

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33564A MA32509B1 (fr) 2008-06-27 2011-01-26 Composes organiques

Country Status (25)

Country Link
US (4) US8791141B2 (fr)
EP (1) EP2307371B1 (fr)
JP (2) JP5542809B2 (fr)
KR (1) KR101264525B1 (fr)
CN (2) CN102076665B (fr)
AR (1) AR072297A1 (fr)
AU (1) AU2009264220B9 (fr)
BR (1) BRPI0914698A2 (fr)
CA (1) CA2729108A1 (fr)
CO (1) CO6321282A2 (fr)
CR (1) CR11861A (fr)
EA (1) EA018731B1 (fr)
EC (1) ECSP10010722A (fr)
ES (1) ES2654044T3 (fr)
HN (1) HN2010002772A (fr)
IL (1) IL209726A0 (fr)
MA (1) MA32509B1 (fr)
MX (1) MX2010014356A (fr)
MY (1) MY153915A (fr)
NZ (1) NZ589666A (fr)
PE (1) PE20100055A1 (fr)
TW (1) TW201004936A (fr)
UY (1) UY31940A (fr)
WO (1) WO2009156462A2 (fr)
ZA (1) ZA201008535B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP2012522806A (ja) * 2009-04-06 2012-09-27 ピーティーシー セラピューティクス，インコーポレーテッド 抗ウイルス処置のためのインドール誘導体および方法
EP2448921A4 (fr) * 2009-04-09 2013-01-23 Msd Kk Dérivés d'aryl-indole
CA2761853A1 (fr) 2009-05-15 2010-11-18 Novartis Ag Derives de benzoxazolone en tant qu'inhibiteurs d'aldosterone synthase
PE20120403A1 (es) 2009-05-15 2012-05-03 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona
KR20120023091A (ko) 2009-05-15 2012-03-12 노파르티스 아게 5-피리딘-3-일-1,3-디히드로-인돌-2-온 유도체, 및 알도스테론 신타제 및/또는 ｃｙｐ11ｂ1의 조절제로서의 그의 용도
TW201107315A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
CN102712589B (zh) * 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
WO2011088188A1 (fr) 2010-01-14 2011-07-21 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
JP5584238B2 (ja) * 2011-01-25 2014-09-03 キッセイ薬品工業株式会社 インドール誘導体、またはその薬理学的に許容される塩の医薬用途
CA2841117A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Derives de 1,2-disubstitue-4-benaylamino-piperidinyl comme inhibiteurs de cetp utiles pour le traitement de l'atherosclerose chez les sujets ayant un niveau eleve de triglycerides
EP2757884B1 (fr) 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Composés pyrazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
WO2013043520A1 (fr) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP2934144B1 (fr) * 2012-12-20 2017-07-19 Merck Sharp & Dohme Corp. Composés d'indazole utiles comme inhibiteurs de l'aldostérone synthase
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
CA2957785C (fr) 2014-08-11 2023-01-03 Angion Biomedica Corporation Inhibiteurs de cytochrome p450 et leurs utilisations
CN104530000B (zh) * 2014-12-12 2016-07-20 重庆博腾制药科技股份有限公司 一种醛固酮合酶调节剂中间体的制备方法
CN107531631B (zh) * 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JP6314196B2 (ja) * 2015-10-22 2018-04-18 田辺三菱製薬株式会社 医薬組成物
KR20180046531A (ko) 2016-10-28 2018-05-09 주식회사 대웅제약 3-아미노알킬레이티드 인돌 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2018125800A2 (fr) * 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Composés inhibiteurs des métalloenzymes
WO2018125799A2 (fr) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Composés inhibiteurs des métalloenzymes
EP3592350A4 (fr) 2017-03-10 2020-12-23 Embera NeuroTherapeutics, Inc. Compositions pharmaceutiques et leurs utilisations
CN107382783B (zh) * 2017-07-17 2019-06-18 中国科学院化学研究所 一种手性β-氨基酸衍生物及其制备方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
KR102220428B1 (ko) * 2018-08-08 2021-02-25 한국과학기술연구원 Ship2 저해활성을 보이는 신규한 피리딘 유도체 및 이를 유효성분으로 하는 약학 조성물
CN109411788B (zh) * 2018-09-28 2021-07-13 北京化工大学 氮杂螺环阳离子负载型聚联苯碱性膜及其制备方法
WO2020102616A1 (fr) * 2018-11-16 2020-05-22 Nimbus Artemis, Inc. Inhibiteurs d'acyle et leurs utilisations
CN113166204A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
EP3887363A1 (fr) 2018-11-27 2021-10-06 Novartis AG Composés pentamères cycliques servant d'inhibiteurs de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) pour le traitement d'un trouble métabolique
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112745270B (zh) * 2020-12-30 2023-02-24 河北医科大学 新化合物及其制备苯唑草酮中间体的方法
CN113943257B (zh) * 2021-09-06 2024-06-14 青岛科技大学 一种光催化c-3位烷基取代喹喔啉-2(1h)-酮类化合物的合成方法及应用
WO2023084449A1 (fr) 2021-11-12 2023-05-19 Novartis Ag Dérivés diaminocyclopentylpyridines pour le traitement d'une maladie ou d'un trouble
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
CN115286790B (zh) * 2022-07-12 2023-05-23 太原理工大学 一种碘捕获材料及其制备方法和应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409626A (en) 1963-09-17 1968-11-05 Neisler Lab Inc Indolylethyl pyridinium quaternary ammonium compounds
US3381006A (en) 1964-10-05 1968-04-30 Mcneilab Inc Certain beta-substituted-alpha-(4, 5-dimethoxy-2-nitrophenyl) acrylonitriles and 2-aminophenyl derivatives thereof
US3467670A (en) 1964-10-05 1969-09-16 Mcneilab Inc 2-phenyl-3-amido-5,6-dimethoxyindoles
US3370063A (en) 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3501310A (en) 1966-03-11 1970-03-17 Eastman Kodak Co Direct positive silver halide emulsions containing compounds which accept electrons and spectrally sensitize the emulsion
US3505070A (en) 1966-03-11 1970-04-07 Eastman Kodak Co Direct positive emulsion containing dimethine dyes containing a 2-aromatically substituted indole nucleus
US3468894A (en) * 1966-11-29 1969-09-23 Geigy Chem Corp Certain 2-pyridyl-substituted indole derivatives
US3501484A (en) * 1968-01-15 1970-03-17 Miles Lab Certain substituted 3 - (2-indolyl)-1,2,5,6-tetrahydropyridines and derivatives thereof
SU557755A3 (ru) * 1968-08-19 1977-05-05 Янссен Фармасьютика Н.В. (Фирма) Способ получени производных имидазола
SU703527A1 (ru) 1978-01-03 1979-12-15 Донецкий государственный университет Способ получени 1-формилкарбазола
US4226868A (en) 1978-09-25 1980-10-07 Eastman Kodak Company Processes for inhibiting the growth of sea urchin eggs
US4232121A (en) 1978-09-25 1980-11-04 Eastman Kodak Company Process for selecting methine dyes which inhibit cell growth
JPS55151505A (en) * 1979-05-14 1980-11-26 Kuraray Co Ltd Indole agricultural and horticultural fungicide
US4355098A (en) 1981-02-11 1982-10-19 E. I. Du Pont De Nemours And Company Supersensitizing direct positive dye combinations
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
GB2111050B (en) * 1981-11-19 1985-09-11 Ciba Geigy Ag N-substituted-2-pyridylindoles
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4950680A (en) 1983-03-31 1990-08-21 Board Of Governors Of Wayne State University Method and compositions for inhibition of tumor cell induced platelet aggregation
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
JPS61282834A (ja) 1985-06-08 1986-12-13 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
DE3530825A1 (de) 1985-08-29 1987-03-05 Boehringer Mannheim Gmbh Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3621761A1 (de) 1986-06-28 1988-01-07 Bayer Ag Indolylpropionsaeuren
GB8626297D0 (en) 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8626296D0 (en) 1986-11-04 1986-12-03 Ici Plc Therapeutic agents
US4839271A (en) 1987-06-26 1989-06-13 E. I. Du Pont De Nemours And Company Direct positive dimethine cyanine dyes containing 1-aryl-2-heteroaryl indole nucleus
EP0300675A3 (fr) 1987-07-21 1990-04-11 Merck Frosst Canada Inc. Méthode pour l'amélioration des traitements par la cyclosporine
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
DE3740985A1 (de) 1987-12-03 1989-06-15 Boehringer Mannheim Gmbh Verwendung linear anellierter tricyclen als hemmer der erythrozytenaggregation
JPH0285251A (ja) 1988-09-22 1990-03-26 Nissan Chem Ind Ltd 植物生長調節剤
US5166170A (en) 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5021448A (en) 1990-02-22 1991-06-04 Ciba-Geigy Corporation Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist
WO1991013872A1 (fr) 1990-03-15 1991-09-19 The Upjohn Company Composes d'indole heterocycliques therapeutiquement utiles
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
FR2679561A1 (fr) 1991-07-26 1993-01-29 Schneider Marc Nouveaux derives de l'(indolyl-1) alkylamine substituee par une chaine presentant des groupements carbonyles conjugues a un noyau aromatique.
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
WO1993019067A1 (fr) 1991-09-12 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Derives d'imidazopyridine utilises en tant qu'antagonistes d'angiotensine ii
JPH07507271A (ja) 1992-03-03 1995-08-10 藤沢薬品工業株式会社 アンジオテンシン１１拮抗剤としてのベンズイミダゾール誘導体
EP0628559B1 (fr) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Composés de pyrimidine et leur application comme agents pharmaceutiques
DE69427283T2 (de) 1993-11-17 2001-09-13 Kyowa Hakko Kogyo Co., Ltd. Propenon-derivate
US5952355A (en) 1993-11-17 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE69705324T2 (de) 1996-12-26 2001-10-11 Nikken Chemicals Co., Ltd. N-hydroxyharnstoffderivate und sie enthaltende medizinische zubereitungen
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
WO1998057937A2 (fr) 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company INHIBITEURS DU FACTEUR Xa COMPRENANT UN GROUPE A SPECIFICITE P1 NEUTRE
AU2201699A (en) 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
KR20010033528A (ko) 1997-12-24 2001-04-25 헨리 필리 파르, 올리비에 보우언 골다공증의 치료를 위한 ａ.ｏ.에 유용한 인돌 유도체
JP2002504539A (ja) 1998-02-25 2002-02-12 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
CN1307576A (zh) 1998-04-29 2001-08-08 美国家用产品公司 5－羟色胺能药物
KR100620772B1 (ko) * 1998-05-15 2006-09-13 와이어쓰 에스트로겐과 2-페닐-1-[4-(2-아미노에톡시)-벤질]-인돌을 포함하는 약제학적 조성물
EP1086950B1 (fr) 1998-05-26 2010-09-29 Chugai Seiyaku Kabushiki Kaisha Derives d'indole heterocycliques et derives de mono ou de di-azaindole
US6436997B1 (en) 1998-06-01 2002-08-20 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension
JPH11344787A (ja) 1998-06-03 1999-12-14 Konica Corp ハロゲン化銀カラー写真感光材料
WO2000015645A1 (fr) 1998-09-11 2000-03-23 Kyorin Pharmaceutical Co., Ltd. Derives d'esters phosphoniques et leur procede de production
EA200100675A1 (ru) 1998-12-18 2001-12-24 Аксис Фармасьютикалз, Инк. Ингибиторы протеазы
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
WO2000044743A1 (fr) 1999-01-28 2000-08-03 Nippon Shinyaku Co., Ltd. Derives d'amides et compositions de medicaments
US6380185B1 (en) * 1999-03-04 2002-04-30 American Home Products Corporation N-substituted benzoyl indoles as estrogenic agents
ATE241621T1 (de) 1999-04-02 2003-06-15 Bristol Myers Squibb Pharma Co Arylsulfonyle als faktor xa inhibitoren
EP1243268A4 (fr) 1999-12-14 2003-05-21 Nippon Shinyaku Co Ltd Composition medicinale
CN1623984A (zh) 1999-12-27 2005-06-08 日本烟草产业株式会社 稠环化合物及其药物用途
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2001089519A1 (fr) 2000-05-22 2001-11-29 Nitromed, Inc. Inhibiteurs de thromboxane, compositions, procedes d'utilisation et applications correspondantes
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
AU2001270200A1 (en) 2000-06-27 2002-01-08 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
AU2001278508A1 (en) 2000-07-31 2002-02-13 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
EP1324985A4 (fr) 2000-10-02 2004-10-06 Merck & Co Inc Inhibiteurs de la prenyl-proteine transferase
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002072549A1 (fr) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Heterocycles fonctionnalises en tant que modulateurs de la fonction du recepteur de chimiokines et procedes de mise en oeuvre
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
DE60229940D1 (de) 2001-07-04 2009-01-02 Lg Electronics Inc Dienstsystem für elektrische haushaltsgeräte und verfahren dafür
ES2309200T3 (es) 2001-10-25 2008-12-16 Asahi Kasei Pharma Corporation Compuesto biciclico.
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
JP2003342276A (ja) 2002-05-24 2003-12-03 Mitsui Chemicals Inc ピロロキナゾリン誘導体及び農園芸用有害生物防除剤ならびにその使用方法
AU2003243709B2 (en) 2002-06-24 2007-01-18 Schering Corporation Indole derivatives useful as histamine H3 antagonists
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
ES2425143T3 (es) * 2002-11-28 2013-10-11 Suven Life Sciences Limited N-Arilsulfonil-3-aminoalcoxiindoles
WO2004048331A1 (fr) * 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalcoxyindoles et leur utilisation en tant que ligands des recepteurs 5-ht
WO2004069394A2 (fr) 2003-02-03 2004-08-19 The Trustees Of Columbia University In The City Of New York Procede synthetique d'arylation directe d'arenes heterocycliques
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
WO2004100998A2 (fr) 2003-05-07 2004-11-25 General Electric Company Compositions et procedes de visualisation non effractive du beta-amyloide soluble
AU2004259703A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
WO2005014543A1 (fr) 2003-08-06 2005-02-17 Japan Tobacco Inc. Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
WO2005016862A1 (fr) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Derive d'acide arylalcanoique substitue et son utilisation
JP4794446B2 (ja) 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリン系カリウムチャンネル阻害薬
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
US20050277639A1 (en) 2004-03-02 2005-12-15 Phil Skolnick 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
AU2005227289B2 (en) 2004-03-08 2012-03-08 Boehringer Ingelheim Pharmaceuticals, Inc. Process for cross coupling indoles
WO2005090302A2 (fr) 2004-03-16 2005-09-29 Boehringer Ingelheim International Gmbh Indolisation catalysee par palladium de 2-bromanilines ou de chloroanilines
US20050245517A1 (en) 2004-04-29 2005-11-03 Phil Skolnick 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2005121132A1 (fr) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. Composé hétérocyclique fondu ayant un effet anti-vhc
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE102004034380A1 (de) 2004-07-16 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verwendung von TRIAL und IkappaB-Kinase Inhibitoren in der Krebsbehandlung
JP2008506744A (ja) 2004-07-20 2008-03-06 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
WO2006010637A2 (fr) 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP5112875B2 (ja) 2004-10-29 2013-01-09 アボット・ラボラトリーズ 新規なキナーゼ阻害薬
WO2006092430A1 (fr) 2005-03-03 2006-09-08 Universität des Saarlandes Inhibiteurs selectifs de synthases de corticoides humaines
CA2602583A1 (fr) 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Amides derives de biaryle modulateurs de recepteur vanilloide vr1
JP2006290791A (ja) 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
WO2007002458A2 (fr) 2005-06-28 2007-01-04 Merck & Co., Inc. Inhibiteurs non nucléosidiques de la transcriptase inverse
WO2007039146A1 (fr) 2005-09-23 2007-04-12 Smithkline Beecham Corporation Derives de 4-carboxy pyrazole utilises en tant qu'agents antiviraux
JP2009512732A (ja) 2005-10-24 2009-03-26 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤および照射の組合せ
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
EP1954276A2 (fr) 2005-11-22 2008-08-13 Merck & Co., Inc. Antagonistes des recepteurs de l'indole orexine
AU2006323986A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
CA2641767A1 (fr) 2006-02-14 2007-08-23 Neurosearch A/S Nouveaux derives de diazabicycloalkane et leur utilisation medicale
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007115231A2 (fr) 2006-03-30 2007-10-11 Chemocentryx, Inc. Modulateurs de cxcr4
AU2007234399A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
JP2009532498A (ja) 2006-04-06 2009-09-10 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ
RU2451018C2 (ru) 2006-04-07 2012-05-20 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы атф-связывающих кассетных транспортеров
GB0610322D0 (en) 2006-05-24 2006-07-05 Karobio Ab Novel pharmaceutical compositions
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
WO2008082487A2 (fr) 2006-12-20 2008-07-10 Schering Corporation Nouveaux inhibiteurs de jnk
CN101636395A (zh) 2007-03-06 2010-01-27 阿斯利康(瑞典)有限公司 新的2-杂芳基取代的吲哚695
US20100087446A1 (en) 2007-04-26 2010-04-08 Chakravarty Prasun K 2-substituted indole derivatives as calcium channel blockers
EP2018861A1 (fr) 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. Ligands 5HT6 comme des dérivés de sulfonamides liés à la prise de poids médicamenteuse
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US20110009453A1 (en) 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.

Also Published As

Publication number Publication date
IL209726A0 (en) 2011-02-28
ZA201008535B (en) 2012-01-25
AU2009264220A1 (en) 2009-12-30
AR072297A1 (es) 2010-08-18
EA201100037A1 (ru) 2011-08-30
ECSP10010722A (es) 2011-01-31
US20140288126A1 (en) 2014-09-25
US20110082129A1 (en) 2011-04-07
JP2014139252A (ja) 2014-07-31
JP2011525894A (ja) 2011-09-29
EP2307371B1 (fr) 2017-10-04
KR20110025223A (ko) 2011-03-09
US8791141B2 (en) 2014-07-29
BRPI0914698A2 (pt) 2015-10-20
EA018731B1 (ru) 2013-10-30
CN102076665B (zh) 2014-09-03
CN104193725A (zh) 2014-12-10
US8030334B2 (en) 2011-10-04
WO2009156462A3 (fr) 2010-05-27
TW201004936A (en) 2010-02-01
MX2010014356A (es) 2011-02-21
UY31940A (es) 2010-01-29
US20150210672A1 (en) 2015-07-30
CN102076665A (zh) 2011-05-25
US20100261698A1 (en) 2010-10-14
HN2010002772A (es) 2013-04-22
EP2307371A2 (fr) 2011-04-13
CR11861A (es) 2011-02-16
JP5753927B2 (ja) 2015-07-22
WO2009156462A2 (fr) 2009-12-30
CA2729108A1 (fr) 2009-12-30
AU2009264220B2 (en) 2012-08-23
PE20100055A1 (es) 2010-02-25
KR101264525B1 (ko) 2013-05-14
JP5542809B2 (ja) 2014-07-09
US9242963B2 (en) 2016-01-26
NZ589666A (en) 2012-06-29
ES2654044T3 (es) 2018-02-12
CO6321282A2 (es) 2011-09-20
CN104193725B (zh) 2016-11-16
AU2009264220B9 (en) 2012-10-04
MY153915A (en) 2015-04-15

Similar Documents

Publication Publication Date Title
MA32509B1 (fr) Composes organiques
AR074631A1 (es) Compuesto de imidazol carboxamida, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la depresion
MA31289B1 (fr) Derives de thiazolidine
MA32941B1 (fr) Composes organiques
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA32536B1 (fr) Composes organiques
MA35903B1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA31708B1 (fr) Associations de principes actifs à propriétés insecticides et acaricides
HRP20070076A2 (en) Pyrimidine derivatives
MA38099A1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MX2009010071A (es) Derivados de aril isoxazolina insecticidas.
MX2010007952A (es) Arilpirrolinas insecticidas.
MA33528B1 (fr) Derives pyridin-4-yliques
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
MX2009008312A (es) Composicion para el cuidado del cabello.
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TNSN08408A1 (fr) PYRIDINE [3,4-b] PYRAZINONES
MA29851B1 (fr) Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
UA106875C2 (uk) Тіадіазолілоксифеніламідини та їх застосування як фунгіцидів
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA30487B1 (fr) Nouveaux composes heterocycliques
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent